Skip to main content
LITTLE GREEN PHARMA LTD logo

LITTLE GREEN PHARMA LTD — Investor Relations & Filings

Ticker · LGP ISIN · AU0000074924 ASX Manufacturing
Open in API
Filings indexed 445 across all filing types
Latest filing 2024-02-18 Regulatory Filings
Country AU Australia
Listing ASX LGP

About LITTLE GREEN PHARMA LTD

https://www.littlegreenpharma.com/

Little Green Pharma Ltd is a vertically integrated medicinal cannabis company focused on the cultivation, production, and distribution of pharmaceutical-grade cannabis medicines. The company operates advanced cultivation and manufacturing facilities, producing a diverse range of products including oils and dried flower. Adhering to Good Manufacturing Practice (GMP) standards, it ensures product consistency and safety across its entire supply chain, from genetics and breeding to final delivery. Little Green Pharma serves both domestic and international markets, maintaining a significant presence in Europe, including Germany and the United Kingdom. The company is committed to advancing clinical research and development to support the therapeutic use of cannabis for various medical conditions, focusing on patient-centric care and high-quality delivery systems.

Recent filings

Filing Released Lang Actions
Final Appendix 3A.5 11 pages 303.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3A.5 Notification of return of capital by way of in specie distribution of securities in another entity' and is structured as a form for notifying the ASX about a return of capital event involving an in specie distribution. It includes detailed questions about the entity, approvals, timetable, and specifics of the return of capital process. The document is regulatory in nature, providing structured information to the stock exchange about a capital return event, specifically a cancellation of a previous in specie distribution announcement. It is not a financial report, earnings release, or management discussion. It is also not a proxy statement, dividend notice, or merger announcement. The document is a formal regulatory filing notifying the market and regulators about a capital return event and its cancellation. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is a notification form rather than a detailed capital change announcement or report.
2024-02-18 English
Investor Webinar & December Quarterly Results Presentation 16 pages 2.1MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 8 February 2024, inviting shareholders to an investor webinar presenting the company's recently reported December quarter financial results. It includes a detailed investor presentation with financial highlights, operational updates, and strategic information. The content focuses on quarterly financial performance, operational activities, and market updates, typical of a quarterly report. The document is about 15,000 characters long, contains substantive financial data and analysis, and is not merely an announcement of a report or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-02-07 English
LGP receives $5 million R&D rebate 2 pages 334.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 1 February 2024, reporting that Little Green Pharma Ltd has received a $5 million research and development rebate. The content focuses on the receipt of a rebate and details about the company's R&D activities and programs. There are no financial statements, quarterly or annual results, or detailed financial performance data included. The document is relatively short (3758 characters) and serves as an update on a specific financial event (receipt of an R&D rebate). It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or officer attestation. The announcement is a capital/financing update related to the company's funding and cash inflows from government rebates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-01-31 English
Quarterly Activities Report & Appendix 4C 22 pages 4.6MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and contains detailed financial and operational data for the quarter ending 31 December 2023. It includes unaudited revenue figures, cash receipts, product sales breakdowns, market updates, and operational highlights. The presence of Appendix 4C, a standard quarterly cash flow report required by the ASX for listed companies, further confirms this is a quarterly report. The document is comprehensive, with substantive financial data and analysis, not merely an announcement or a brief summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-01-30 English
Extension of Reset Offers and change of General Meeting date 2 pages 275.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Little Green Pharma Ltd regarding the extension of a capital raising offer and the change of date for an Extraordinary General Meeting (EGM). It details the new dates for the closing of the offer and the EGM, instructions for voting and submitting questions, and a timetable for related events including the demerger and distribution of shares. The content focuses on notifying shareholders about changes to meeting dates and capital raising offers, rather than presenting financial results, detailed reports, or management discussions. The document is relatively short (4240 characters) and serves as a formal notification of changes to shareholder meeting arrangements and capital raising timelines. This fits best with the category of Capital/Financing Update (CAP), as it relates to updates on fundraising activities and shareholder meetings connected to those activities.
2024-01-16 English
Updated Appendix 3A.5 11 pages 307.0KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3A.5 form titled 'Notification of return of capital by way of in specie distribution of securities in another entity.' It is a regulatory form submitted to the ASX (Australian Securities Exchange) concerning a return of capital event, specifically an in specie distribution. The document includes detailed timetable information, approvals, and procedural details related to the return of capital. It is not a financial report, earnings release, or management discussion but a formal regulatory announcement about a capital return event. The document is lengthy (15,000 characters) and contains substantive information about the capital return process, approvals, and dates. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure and financing events. It is not a report publication announcement or a regulatory filing fallback because it contains detailed substantive information rather than just a notice or certification.
2024-01-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.